These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 20661166)
1. Role of FDG PET-CT in recurrent renal cell carcinoma. Kumar R; Shandal V; Shamim SA; Jeph S; Singh H; Malhotra A Nucl Med Commun; 2010 Oct; 31(10):844-50. PubMed ID: 20661166 [TBL] [Abstract][Full Text] [Related]
2. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376 [TBL] [Abstract][Full Text] [Related]
4. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. Park JW; Jo MK; Lee HM BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of F-18 FDG PET/CT for local and distant disease relapse surveillance in surgically treated RCC patients: Can it aid in establishing consensus follow up strategy? Elahmadawy MA; Elazab MSS; Ahmed S; Salama M Nucl Med Rev Cent East Eur; 2018; 21(2):85-91. PubMed ID: 30070347 [TBL] [Abstract][Full Text] [Related]
7. The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Nakatani K; Nakamoto Y; Saga T; Higashi T; Togashi K Eur J Radiol; 2011 Jul; 79(1):29-35. PubMed ID: 20015602 [TBL] [Abstract][Full Text] [Related]
8. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227 [TBL] [Abstract][Full Text] [Related]
9. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344 [TBL] [Abstract][Full Text] [Related]
10. Clinical utility of Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538 [TBL] [Abstract][Full Text] [Related]
11. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. Kang DE; White RL; Zuger JH; Sasser HC; Teigland CM J Urol; 2004 May; 171(5):1806-9. PubMed ID: 15076281 [TBL] [Abstract][Full Text] [Related]
12. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level. Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474 [TBL] [Abstract][Full Text] [Related]
13. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer. Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451 [TBL] [Abstract][Full Text] [Related]
14. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma. Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314 [TBL] [Abstract][Full Text] [Related]
15. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Skoura E; Rondogianni P; Alevizaki M; Tzanela M; Tsagarakis S; Piaditis G; Tolis G; Datseris IE Nucl Med Commun; 2010 Jun; 31(6):567-75. PubMed ID: 20335822 [TBL] [Abstract][Full Text] [Related]
16. F-18 FDG PET in detecting renal cell carcinoma. Ak I; Can C Acta Radiol; 2005 Dec; 46(8):895-9. PubMed ID: 16392617 [TBL] [Abstract][Full Text] [Related]